Trump promotes reduced drug prices as GOP prepares for 2026: ‘I AM THE PRESIDENT OF AFFORDABILITY’

On Saturday, President Trump emphasized the significant decline in drug prices under his administration, suggesting it could be a major advantage for Republicans in the 2026 midterm elections. Writing on Truth Social, Trump stated that by implementing Favored Nations Status for the United States, drug costs have fallen to unprecedented levels, citing reductions of 500%, 600%, 700%, and beyond.

The president praised his own efforts, reminding Republicans that this was done by us, and nobody else. He called the initiative a revolution in medicine, the biggest and most important event, ever. Trump further asserted that if the story of these price reductions is effectively communicated, the GOP could achieve record-breaking midterm victories, dubbing himself the Affordability President.

Under Trumps leadership, several agreements with pharmaceutical companies have aimed to lower medication costs. Earlier this month, deals were struck with Novo Nordisk and Eli Lilly to offer their GLP-1 weight loss medications at reduced prices. In the previous month, AstraZeneca committed to maintaining drug prices for Medicaid recipients at levels matching the lowest international prices. Most of AstraZenecas products are planned to be listed on TrumpRx.com, in line with the administrations most favored nation executive order issued in July. Pfizer was the first manufacturer to comply with this order in September.

Amid growing voter concern over affordability and living expenses, Trumps approach to challenging Big Pharma has received broad support. A recent survey by the Pharmaceutical Reform Alliance, conducted by National Research Inc., found that 86% of Americans back Trumps health initiatives and would support candidates advocating for MFN policies. Additionally, 85% of respondents reported that prescription medications have become more expensive, with most attributing the high costs to pharmaceutical companies.

Affordability emerged as a major topic during the 2025 elections and the record-length government shutdown, even as Democrats captured key races. Trump dismissed concerns that rising prices could threaten Republican seats in 2026, calling such warnings a con job by the Democrats. He has also claimed the issue of affordability is effectively resolved, citing lower Thanksgiving meal costs as evidence. Walmart said yesterday that the Thanksgiving dinner was 25 percent more expensive under former President Biden, he remarked, emphasizing Walmarts influence.

Analysis: Trump's Bold Claims on Drug Price Reductions and Their Political Implications

In his recent social media post, President Trump highlighted the significant reductions in drug prices under his administration, framing it as a potential game-changer for Republicans in the upcoming 2026 midterm elections. Trump's assertion that his policies, particularly the "Favored Nations Status," have driven drug prices to historically low levels is a key part of his messaging strategy. He pointed to price reductions ranging from 500% to over 700%, underscoring these as a direct result of his administration's actions.

However, while Trump's claims are framed in terms of victory, it is essential to consider the broader context. Several pharmaceutical agreements have been struck under Trump's leadership, such as with Novo Nordisk, Eli Lilly, and AstraZeneca. These deals aim to reduce medication costs, particularly for weight loss drugs and Medicaid recipients. The administration's executive order for "most favored nation" pricing, which requires drug manufacturers to match international prices, is at the heart of these efforts. Pfizer's early compliance with the order in September exemplifies the momentum behind these reforms.

Yet, despite these reductions, the public's perception of affordability remains a crucial factor. A recent survey by the Pharmaceutical Reform Alliance shows that the majority of Americans support Trump's health initiatives. With 86% backing the MFN policies, this could translate into significant political capital for Republicans. At the same time, 85% of respondents acknowledged rising drug prices, blaming pharmaceutical companies, thus reinforcing the political utility of Trump's stance against "Big Pharma."

Trump's dismissal of concerns over potential voter backlash regarding rising prices, especially in light of the 2025 elections and the prolonged government shutdown, shows his confidence in the effectiveness of his approach. However, the question remains whether the affordability issue, which has dominated recent elections, can be fully resolved or if it will continue to play a pivotal role in shaping voter sentiment ahead of 2026.

In conclusion, while the reductions in drug prices under Trump's administration are significant, the political ramifications of these changes remain to be fully seen. As affordability remains a key concern for voters, Trump's ability to position himself as the "Affordability President" will likely be a defining narrative in the run-up to the 2026 midterms.

Sources:

• Trump touts lower drug prices as GOP preps for 2026: ‘I AM THE AFFORDABILITY PRESIDENT’